A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

NCT IDNCT06124157ClinicalTrials.gov data as of Apr 2026

Check if I qualify Back to results ClinicalTrials.gov

Phase

Phase 2

Target enrollment

222

Study length

about 5.5 years

Ages

1.00207396455779–46

Locations

130 sites in AL, AR, AZ +41

What this study is about

This trial is testing a treatment with blinatumomab, dasatinib or imatinib, and standard chemotherapy for children, adolescents, and young adults with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-Like) B-cell acute lymphoblastic leukemia (B-ALL). The goal is to see if combining these treatments improves outcomes compared to using dasatinib or imatinib alone with chemotherapy.

Simplified from trial records by PatientMatch.

What you may be asked to do

1.Receive Blinatumomab
2.Receive Radiation Therapy
3.Take Calaspargase Pegol
+3 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel

In-person visits

Requires travel to a study site

Physical Intervention

Injection / IVInjection / IV

How treatment is administered

Treatment Assignment

All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

blinatumomab, calaspargase pegol, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), cytarabine, dasatinib, daunorubicin, doxorubicin (Anthracycline chemotherapy; intercalates DNA and inhibits topoisomerase II), imatinib (Tyrosine kinase inhibitor; blocks BCR-ABL oncogene signal)

Drug routes

injection, intravenous, infusion, injection (Injection), oral (Oral Tablet), oral (Disintegrating Oral Tablet), oral

Endpoints

Primary: ABL-class Ph-like B-ALL 3-year event free survival (EFS), Incidence of adverse events, Philadelphia chromosome-positive (Ph+) (BCR::ABL1-rearranged) 3-year event free survival (EFS)

Secondary: 3-year EFS, 3-year disease free survival, 3-year overall survival (OS), OS of patients with ABL-class Ph-like B-ALL

Procedures

diagnostic, biopsy, imaging, radiation

Body systems

Oncology

Screen for this study View on ClinicalTrials.gov